Coverage Decisions For AlloMap Molecular Testing To Detect Cardiac Allograft Rejections Left Up To MACs
Executive Summary
The US CMS has proposed that due to low Medicare use, it will not nationally cover AlloMap molecular tests to detect cardiac allograft rejections.
You may also be interested in...
Buying The Most Time: CareDx’s Diagnostics For Transplant Recipients
An organ transplant is not a “one and done” procedure, and patients require lifelong post-operative monitoring. Medtech Insight spoke to CareDx about how monitoring could improve patient outcomes.
Lab Sector Vs. CMS Battle Heats Up As Medicare Agency Moves Forward With 2018 Rates
Test-makers and labs say the agency is missing large swaths of the market in making its "market-based" lab payment calculation, but CMS stands by its data, and finalized 2018 lab fee schedule rates. Could next steps be in Congress, or the courts?
White House To Deliver 25 Million Face Masks To Low-Income Americans
The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.